ID   PCAT2_HUMAN             Reviewed;         544 AA.
AC   Q7L5N7; A3KBM1; Q6MZJ6; Q9NX23;
DT   25-JUL-2006, integrated into UniProtKB/Swiss-Prot.
DT   05-JUL-2004, sequence version 1.
DT   18-JUN-2025, entry version 171.
DE   RecName: Full=Lysophosphatidylcholine acyltransferase 2;
DE            Short=LPC acyltransferase 2;
DE            Short=LPCAT-2;
DE            Short=LysoPC acyltransferase 2;
DE            EC=2.3.1.23 {ECO:0000269|PubMed:21498505};
DE   AltName: Full=1-acylglycerol-3-phosphate O-acyltransferase 11;
DE            Short=1-AGP acyltransferase 11;
DE            Short=1-AGPAT 11;
DE            EC=2.3.1.51 {ECO:0000269|PubMed:20363836};
DE   AltName: Full=1-acylglycerophosphocholine O-acyltransferase;
DE   AltName: Full=1-alkenylglycerophosphocholine O-acyltransferase;
DE            EC=2.3.1.25 {ECO:0000250|UniProtKB:Q8BYI6};
DE   AltName: Full=1-alkylglycerophosphocholine O-acetyltransferase;
DE            EC=2.3.1.67 {ECO:0000269|PubMed:17182612};
DE   AltName: Full=Acetyl-CoA:lyso-platelet-activating factor acetyltransferase;
DE            Short=Acetyl-CoA:lyso-PAF acetyltransferase;
DE            Short=Lyso-PAF acetyltransferase;
DE            Short=LysoPAFAT;
DE   AltName: Full=Acyltransferase-like 1;
DE   AltName: Full=Lysophosphatidic acid acyltransferase alpha;
DE            Short=LPAAT-alpha;
GN   Name=LPCAT2; Synonyms=AGPAT11, AYTL1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=17182612; DOI=10.1074/jbc.m609641200;
RA   Shindou H., Hishikawa D., Nakanishi H., Harayama T., Ishii S., Taguchi R.,
RA   Shimizu T.;
RT   "A single enzyme catalyzes both platelet-activating factor production and
RT   membrane biogenesis of inflammatory cells. Cloning and characterization of
RT   acetyl-CoA:lyso-PAF acetyltransferase.";
RL   J. Biol. Chem. 282:6532-6539(2007).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Carcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Fetal kidney;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION.
RX   PubMed=20363836; DOI=10.1194/jlr.m004762;
RA   Agarwal A.K., Garg A.;
RT   "Enzymatic activity of the human 1-acylglycerol-3-phosphate-O-
RT   acyltransferase isoform 11: upregulated in breast and cervical cancers.";
RL   J. Lipid Res. 51:2143-2152(2010).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [7]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND TOPOLOGY.
RX   PubMed=21498505; DOI=10.1074/jbc.m110.202424;
RA   Moessinger C., Kuerschner L., Spandl J., Shevchenko A., Thiele C.;
RT   "Human lysophosphatidylcholine acyltransferases 1 and 2 are located in
RT   lipid droplets where they catalyze the formation of phosphatidylcholine.";
RL   J. Biol. Chem. 286:21330-21339(2011).
RN   [8]
RP   FUNCTION.
RX   PubMed=25491198; DOI=10.1186/s12860-014-0043-3;
RA   Moessinger C., Klizaite K., Steinhagen A., Philippou-Massier J.,
RA   Shevchenko A., Hoch M., Ejsing C.S., Thiele C.;
RT   "Two different pathways of phosphatidylcholine synthesis, the Kennedy
RT   Pathway and the Lands Cycle, differentially regulate cellular
RT   triacylglycerol storage.";
RL   BMC Cell Biol. 15:43-43(2014).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
CC   -!- FUNCTION: Exhibits both acyltransferase and acetyltransferase
CC       activities (PubMed:17182612, PubMed:20363836, PubMed:21498505).
CC       Catalyzes the conversion of lysophosphatidylcholine (1-acyl-sn-glycero-
CC       3-phosphocholine or LPC) into phosphatidylcholine (1,2-diacyl-sn-
CC       glycero-3-phosphocholine or PC) (PubMed:21498505). Catalyzes the
CC       conversion 1-acyl-sn-glycerol-3-phosphate (lysophosphatidic acid or
CC       LPA) into 1,2-diacyl-sn-glycerol-3-phosphate (phosphatidic acid or PA)
CC       by incorporating an acyl moiety at the sn-2 position of the glycerol
CC       backbone (PubMed:20363836). Involved in platelet-activating factor
CC       (PAF) biosynthesis by catalyzing the conversion of the PAF precursor,
CC       1-O-alkyl-sn-glycero-3-phosphocholine (lyso-PAF) into 1-O-alkyl-2-
CC       acetyl-sn-glycero-3-phosphocholine (PAF) (PubMed:17182612). Also
CC       converts lyso-PAF to 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine (PC),
CC       a major component of cell membranes and a PAF precursor (By
CC       similarity). Under resting conditions, acyltransferase activity is
CC       preferred (By similarity). Upon acute inflammatory stimulus,
CC       acetyltransferase activity is enhanced and PAF synthesis increases (By
CC       similarity). Involved in the regulation of lipid droplet number and
CC       size (PubMed:25491198). {ECO:0000250|UniProtKB:Q8BYI6,
CC       ECO:0000269|PubMed:17182612, ECO:0000269|PubMed:20363836,
CC       ECO:0000269|PubMed:21498505, ECO:0000269|PubMed:25491198}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1-acyl-sn-glycero-3-phosphocholine + an acyl-CoA = a 1,2-
CC         diacyl-sn-glycero-3-phosphocholine + CoA; Xref=Rhea:RHEA:12937,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57643, ChEBI:CHEBI:58168,
CC         ChEBI:CHEBI:58342; EC=2.3.1.23;
CC         Evidence={ECO:0000269|PubMed:21498505};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1-O-alkyl-sn-glycero-3-phosphocholine + acetyl-CoA = a 1-O-
CC         alkyl-2-acetyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:18461, ChEBI:CHEBI:30909, ChEBI:CHEBI:36707,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57288; EC=2.3.1.67;
CC         Evidence={ECO:0000269|PubMed:17182612};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1-acyl-sn-glycero-3-phosphate + an acyl-CoA = a 1,2-diacyl-
CC         sn-glycero-3-phosphate + CoA; Xref=Rhea:RHEA:19709,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57970, ChEBI:CHEBI:58342,
CC         ChEBI:CHEBI:58608; EC=2.3.1.51;
CC         Evidence={ECO:0000269|PubMed:20363836};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1-O-(1Z-alkenyl)-sn-glycero-3-phosphocholine + an acyl-CoA =
CC         a 1-O-(1Z-alkenyl)-2-acyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:10344, ChEBI:CHEBI:57287, ChEBI:CHEBI:58342,
CC         ChEBI:CHEBI:77286, ChEBI:CHEBI:77287; EC=2.3.1.25;
CC         Evidence={ECO:0000250|UniProtKB:Q8BYI6};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-sn-glycero-3-phosphate + (9Z)-octadecenoyl-CoA
CC         = 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphate + CoA;
CC         Xref=Rhea:RHEA:33187, ChEBI:CHEBI:57287, ChEBI:CHEBI:57387,
CC         ChEBI:CHEBI:57518, ChEBI:CHEBI:64839;
CC         Evidence={ECO:0000269|PubMed:20363836};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:33188;
CC         Evidence={ECO:0000305|PubMed:20363836};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-(9Z-octadecenoyl)-sn-glycero-3-phosphate + (9Z)-
CC         octadecenoyl-CoA = 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphate +
CC         CoA; Xref=Rhea:RHEA:37131, ChEBI:CHEBI:57287, ChEBI:CHEBI:57387,
CC         ChEBI:CHEBI:74544, ChEBI:CHEBI:74546;
CC         Evidence={ECO:0000269|PubMed:20363836};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37132;
CC         Evidence={ECO:0000305|PubMed:20363836};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-(9Z-octadecenoyl)-sn-glycero-3-phosphate + hexadecanoyl-CoA
CC         = 1-(9Z)-octadecenoyl-2-hexadecanoyl-sn-glycero-3-phosphate + CoA;
CC         Xref=Rhea:RHEA:37143, ChEBI:CHEBI:57287, ChEBI:CHEBI:57379,
CC         ChEBI:CHEBI:74544, ChEBI:CHEBI:74551;
CC         Evidence={ECO:0000269|PubMed:20363836};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37144;
CC         Evidence={ECO:0000305|PubMed:20363836};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-heptadecanoyl-sn-glycero-3-phosphate + (9Z)-octadecenoyl-CoA
CC         = 1-heptadecanoyl-2-(9Z)-octadecenoyl-sn-glycero-3-phosphate + CoA;
CC         Xref=Rhea:RHEA:37151, ChEBI:CHEBI:57287, ChEBI:CHEBI:57387,
CC         ChEBI:CHEBI:74554, ChEBI:CHEBI:74556;
CC         Evidence={ECO:0000269|PubMed:20363836};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37152;
CC         Evidence={ECO:0000305|PubMed:20363836};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-octadecanoyl-sn-glycero-3-phosphate + (9Z)-octadecenoyl-CoA
CC         = 1-octadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphate + CoA;
CC         Xref=Rhea:RHEA:37163, ChEBI:CHEBI:57287, ChEBI:CHEBI:57387,
CC         ChEBI:CHEBI:74560, ChEBI:CHEBI:74565;
CC         Evidence={ECO:0000269|PubMed:20363836};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37164;
CC         Evidence={ECO:0000305|PubMed:20363836};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=heptadecanoyl-CoA + 1-(9Z-octadecenoyl)-sn-glycero-3-phosphate
CC         = 1-(9Z)-octadecenoyl-2-heptadecanoyl-sn-glycero-3-phosphate + CoA;
CC         Xref=Rhea:RHEA:37155, ChEBI:CHEBI:57287, ChEBI:CHEBI:74307,
CC         ChEBI:CHEBI:74544, ChEBI:CHEBI:74558;
CC         Evidence={ECO:0000269|PubMed:20363836};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37156;
CC         Evidence={ECO:0000305|PubMed:20363836};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-(9Z-octadecenoyl)-sn-glycero-3-phosphate + (9Z,12Z)-
CC         octadecadienoyl-CoA = 1-(9Z)-octadecenoyl-2-(9Z,12Z)-octadecadienoyl-
CC         sn-glycero-3-phosphate + CoA; Xref=Rhea:RHEA:37159,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57383, ChEBI:CHEBI:74544,
CC         ChEBI:CHEBI:74563; Evidence={ECO:0000269|PubMed:20363836};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37160;
CC         Evidence={ECO:0000305|PubMed:20363836};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-(9Z-octadecenoyl)-sn-glycero-3-phosphate + tetradecanoyl-CoA
CC         = 1-(9Z)-octadecenoyl-2-tetradecanoyl-sn-glycero-3-phosphate + CoA;
CC         Xref=Rhea:RHEA:37171, ChEBI:CHEBI:57287, ChEBI:CHEBI:57385,
CC         ChEBI:CHEBI:74544, ChEBI:CHEBI:74579;
CC         Evidence={ECO:0000269|PubMed:20363836};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37172;
CC         Evidence={ECO:0000305|PubMed:20363836};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=pentadecanoyl-CoA + 1-(9Z-octadecenoyl)-sn-glycero-3-phosphate
CC         = 1-(9Z)-octadecenoyl-2-pentadecanoyl-sn-glycero-3-phosphate + CoA;
CC         Xref=Rhea:RHEA:37175, ChEBI:CHEBI:57287, ChEBI:CHEBI:74309,
CC         ChEBI:CHEBI:74544, ChEBI:CHEBI:74578;
CC         Evidence={ECO:0000269|PubMed:20363836};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37176;
CC         Evidence={ECO:0000305|PubMed:20363836};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=nonadecanoyl-CoA + 1-(9Z-octadecenoyl)-sn-glycero-3-phosphate
CC         = 1-(9Z)-octadecenoyl-2-nonadecanoyl-sn-glycero-3-phosphate + CoA;
CC         Xref=Rhea:RHEA:37595, ChEBI:CHEBI:57287, ChEBI:CHEBI:74544,
CC         ChEBI:CHEBI:75104, ChEBI:CHEBI:75105;
CC         Evidence={ECO:0000269|PubMed:20363836};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37596;
CC         Evidence={ECO:0000305|PubMed:20363836};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-sn-glycero-3-phosphocholine + (9Z)-
CC         octadecenoyl-CoA = 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-
CC         phosphocholine + CoA; Xref=Rhea:RHEA:35991, ChEBI:CHEBI:57287,
CC         ChEBI:CHEBI:57387, ChEBI:CHEBI:72998, ChEBI:CHEBI:73001;
CC         Evidence={ECO:0000269|PubMed:21498505};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:35992;
CC         Evidence={ECO:0000305|PubMed:21498505};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-O-hexadecyl-sn-glycero-3-phosphocholine + acetyl-CoA = 1-O-
CC         hexadecyl-2-acetyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:37719, ChEBI:CHEBI:44811, ChEBI:CHEBI:57287,
CC         ChEBI:CHEBI:57288, ChEBI:CHEBI:64496;
CC         Evidence={ECO:0000269|PubMed:17182612};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37720;
CC         Evidence={ECO:0000305|PubMed:17182612};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-O-octadecyl-sn-glycero-3-phosphocholine + acetyl-CoA = 1-O-
CC         octadecyl-2-acetyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:37699, ChEBI:CHEBI:52450, ChEBI:CHEBI:57287,
CC         ChEBI:CHEBI:57288, ChEBI:CHEBI:75216;
CC         Evidence={ECO:0000250|UniProtKB:Q8BYI6};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37700;
CC         Evidence={ECO:0000250|UniProtKB:Q8BYI6};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-sn-glycero-3-phosphocholine + acetyl-CoA = 1-
CC         hexadecanoyl-2-acetyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:37703, ChEBI:CHEBI:57287, ChEBI:CHEBI:57288,
CC         ChEBI:CHEBI:72998, ChEBI:CHEBI:75219;
CC         Evidence={ECO:0000250|UniProtKB:Q8BYI6};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37704;
CC         Evidence={ECO:0000250|UniProtKB:Q8BYI6};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-octadecanoyl-sn-glycero-3-phosphocholine + acetyl-CoA = 1-
CC         octadecanoyl-2-acetyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:37707, ChEBI:CHEBI:57287, ChEBI:CHEBI:57288,
CC         ChEBI:CHEBI:73858, ChEBI:CHEBI:75220;
CC         Evidence={ECO:0000250|UniProtKB:Q8BYI6};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37708;
CC         Evidence={ECO:0000250|UniProtKB:Q8BYI6};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1-O-(1Z-alkenyl)-sn-glycero-3-phosphocholine + acetyl-CoA =
CC         1-O-(1Z)-alkenyl-2-acetyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:37711, ChEBI:CHEBI:57287, ChEBI:CHEBI:57288,
CC         ChEBI:CHEBI:77287, ChEBI:CHEBI:78566;
CC         Evidence={ECO:0000250|UniProtKB:Q8BYI6};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37712;
CC         Evidence={ECO:0000250|UniProtKB:Q8BYI6};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-O-octadecyl-sn-glycero-3-phosphocholine + (5Z,8Z,11Z,14Z)-
CC         eicosatetraenoyl-CoA = 1-O-octadecyl-2-(5Z,8Z,11Z,14Z)-
CC         eicosatetraenoyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:37747, ChEBI:CHEBI:57287, ChEBI:CHEBI:57368,
CC         ChEBI:CHEBI:75216, ChEBI:CHEBI:75245;
CC         Evidence={ECO:0000250|UniProtKB:Q8BYI6};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:37748;
CC         Evidence={ECO:0000250|UniProtKB:Q8BYI6};
CC   -!- PATHWAY: Lipid metabolism; phospholipid metabolism.
CC   -!- INTERACTION:
CC       Q7L5N7; Q15125: EBP; NbExp=3; IntAct=EBI-4280011, EBI-3915253;
CC       Q7L5N7; Q9Y282: ERGIC3; NbExp=3; IntAct=EBI-4280011, EBI-781551;
CC       Q7L5N7; Q7Z5P4: HSD17B13; NbExp=3; IntAct=EBI-4280011, EBI-18053395;
CC       Q7L5N7; P48051: KCNJ6; NbExp=3; IntAct=EBI-4280011, EBI-12017638;
CC       Q7L5N7; Q5SR56: MFSD14B; NbExp=3; IntAct=EBI-4280011, EBI-373355;
CC       Q7L5N7; Q86VR2: RETREG3; NbExp=3; IntAct=EBI-4280011, EBI-10192441;
CC       Q7L5N7; Q8TEB9: RHBDD1; NbExp=3; IntAct=EBI-4280011, EBI-9916444;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:20363836, ECO:0000269|PubMed:21498505}; Single-pass
CC       type II membrane protein {ECO:0000269|PubMed:21498505}. Golgi apparatus
CC       membrane {ECO:0000250|UniProtKB:Q8BYI6}; Single-pass type II membrane
CC       protein {ECO:0000305|PubMed:21498505}. Cell membrane
CC       {ECO:0000250|UniProtKB:Q8BYI6}; Single-pass type II membrane protein
CC       {ECO:0000305|PubMed:21498505}. Lipid droplet
CC       {ECO:0000269|PubMed:21498505}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q7L5N7-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q7L5N7-2; Sequence=VSP_019912;
CC   -!- DOMAIN: The HXXXXD motif is essential for acyltransferase activity.
CC       {ECO:0000250|UniProtKB:Q3TFD2}.
CC   -!- SIMILARITY: Belongs to the 1-acyl-sn-glycerol-3-phosphate
CC       acyltransferase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA91199.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=CAE46034.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB244718; BAF47696.1; -; mRNA.
DR   EMBL; AK000488; BAA91199.1; ALT_FRAME; mRNA.
DR   EMBL; BX641069; CAE46034.1; ALT_FRAME; mRNA.
DR   EMBL; BC002472; AAH02472.2; -; mRNA.
DR   CCDS; CCDS10753.1; -. [Q7L5N7-1]
DR   RefSeq; NP_060309.2; NM_017839.4. [Q7L5N7-1]
DR   RefSeq; XP_011521471.1; XM_011523169.4. [Q7L5N7-2]
DR   RefSeq; XP_054236563.1; XM_054380588.1. [Q7L5N7-2]
DR   AlphaFoldDB; Q7L5N7; -.
DR   SMR; Q7L5N7; -.
DR   BioGRID; 120286; 120.
DR   FunCoup; Q7L5N7; 1005.
DR   IntAct; Q7L5N7; 60.
DR   MINT; Q7L5N7; -.
DR   STRING; 9606.ENSP00000262134; -.
DR   DrugBank; DB15584; Luteolin.
DR   DrugBank; DB04216; Quercetin.
DR   SwissLipids; SLP:000000279; -.
DR   GlyGen; Q7L5N7; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q7L5N7; -.
DR   PhosphoSitePlus; Q7L5N7; -.
DR   SwissPalm; Q7L5N7; -.
DR   BioMuta; LPCAT2; -.
DR   DMDM; 74738601; -.
DR   jPOST; Q7L5N7; -.
DR   MassIVE; Q7L5N7; -.
DR   PaxDb; 9606-ENSP00000262134; -.
DR   PeptideAtlas; Q7L5N7; -.
DR   ProteomicsDB; 68812; -. [Q7L5N7-1]
DR   ProteomicsDB; 68813; -. [Q7L5N7-2]
DR   Pumba; Q7L5N7; -.
DR   Antibodypedia; 2010; 191 antibodies from 28 providers.
DR   DNASU; 54947; -.
DR   Ensembl; ENST00000262134.10; ENSP00000262134.5; ENSG00000087253.13. [Q7L5N7-1]
DR   GeneID; 54947; -.
DR   KEGG; hsa:54947; -.
DR   MANE-Select; ENST00000262134.10; ENSP00000262134.5; NM_017839.5; NP_060309.2.
DR   UCSC; uc002eie.5; human. [Q7L5N7-1]
DR   AGR; HGNC:26032; -.
DR   CTD; 54947; -.
DR   DisGeNET; 54947; -.
DR   GeneCards; LPCAT2; -.
DR   HGNC; HGNC:26032; LPCAT2.
DR   HPA; ENSG00000087253; Tissue enhanced (bone marrow, thyroid gland).
DR   MalaCards; LPCAT2; -.
DR   MIM; 612040; gene.
DR   OpenTargets; ENSG00000087253; -.
DR   VEuPathDB; HostDB:ENSG00000087253; -.
DR   eggNOG; KOG4666; Eukaryota.
DR   GeneTree; ENSGT01030000234574; -.
DR   HOGENOM; CLU_025017_0_0_1; -.
DR   InParanoid; Q7L5N7; -.
DR   OMA; FLYHKSE; -.
DR   OrthoDB; 272512at2759; -.
DR   PAN-GO; Q7L5N7; 0 GO annotations based on evolutionary models.
DR   PhylomeDB; Q7L5N7; -.
DR   BRENDA; 2.3.1.23; 2681.
DR   BRENDA; 2.3.1.51; 2681.
DR   BRENDA; 2.3.1.67; 2681.
DR   PathwayCommons; Q7L5N7; -.
DR   Reactome; R-HSA-1482788; Acyl chain remodelling of PC.
DR   SignaLink; Q7L5N7; -.
DR   SIGNOR; Q7L5N7; -.
DR   UniPathway; UPA00085; -.
DR   BioGRID-ORCS; 54947; 8 hits in 1154 CRISPR screens.
DR   ChiTaRS; LPCAT2; human.
DR   GenomeRNAi; 54947; -.
DR   Pharos; Q7L5N7; Tbio.
DR   PRO; PR:Q7L5N7; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   RNAct; Q7L5N7; protein.
DR   Bgee; ENSG00000087253; Expressed in caput epididymis and 167 other cell types or tissues.
DR   ExpressionAtlas; Q7L5N7; baseline and differential.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005795; C:Golgi stack; ISS:UniProtKB.
DR   GO; GO:0005811; C:lipid droplet; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0003841; F:1-acylglycerol-3-phosphate O-acyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0047184; F:1-acylglycerophosphocholine O-acyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0047192; F:1-alkylglycerophosphocholine O-acetyltransferase activity; ISS:UniProtKB.
DR   GO; GO:0047144; F:2-acylglycerol-3-phosphate O-acyltransferase activity; TAS:Reactome.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0042171; F:lysophosphatidic acid acyltransferase activity; IBA:GO_Central.
DR   GO; GO:0047159; F:plasmalogen synthase activity; IEA:UniProtKB-EC.
DR   GO; GO:0061024; P:membrane organization; ISS:UniProtKB.
DR   GO; GO:0036151; P:phosphatidylcholine acyl-chain remodeling; IDA:UniProtKB.
DR   GO; GO:0006663; P:platelet activating factor biosynthetic process; ISS:UniProtKB.
DR   CDD; cd00051; EFh; 2.
DR   CDD; cd07991; LPLAT_LPCAT1-like; 1.
DR   FunFam; 1.10.238.10:FF:000160; Lysophosphatidylcholine acyltransferase 2; 1.
DR   Gene3D; 1.10.238.10; EF-hand; 1.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR018247; EF_Hand_1_Ca_BS.
DR   InterPro; IPR002048; EF_hand_dom.
DR   InterPro; IPR045252; LPCAT1-like.
DR   InterPro; IPR002123; Plipid/glycerol_acylTrfase.
DR   PANTHER; PTHR23063:SF21; LYSOPHOSPHATIDYLCHOLINE ACYLTRANSFERASE 2; 1.
DR   PANTHER; PTHR23063; PHOSPHOLIPID ACYLTRANSFERASE; 1.
DR   Pfam; PF01553; Acyltransferase; 1.
DR   Pfam; PF13202; EF-hand_5; 1.
DR   Pfam; PF13499; EF-hand_7; 1.
DR   PRINTS; PR00450; RECOVERIN.
DR   SMART; SM00054; EFh; 2.
DR   SMART; SM00563; PlsC; 1.
DR   SUPFAM; SSF47473; EF-hand; 1.
DR   SUPFAM; SSF69593; Glycerol-3-phosphate (1)-acyltransferase; 1.
DR   PROSITE; PS00018; EF_HAND_1; 2.
DR   PROSITE; PS50222; EF_HAND_2; 2.
DR   neXtProt; NX_Q7L5N7; -.
DR   PharmGKB; PA162394265; -.
DR   TreeFam; TF323244; -.
PE   1: Evidence at protein level;
KW   Acyltransferase; Alternative splicing; Calcium; Cell membrane;
KW   Endoplasmic reticulum; Golgi apparatus; Lipid biosynthesis; Lipid droplet;
KW   Lipid metabolism; Membrane; Metal-binding; Phospholipid biosynthesis;
KW   Phospholipid metabolism; Proteomics identification; Reference proteome;
KW   Repeat; Signal-anchor; Transferase; Transmembrane; Transmembrane helix.
FT   CHAIN           1..544
FT                   /note="Lysophosphatidylcholine acyltransferase 2"
FT                   /id="PRO_0000247058"
FT   TOPO_DOM        1..57
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        58..78
FT                   /note="Helical; Signal-anchor for type II membrane protein"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        79..544
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          391..426
FT                   /note="EF-hand 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   DOMAIN          428..463
FT                   /note="EF-hand 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   REGION          518..544
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           146..151
FT                   /note="HXXXXD motif"
FT                   /evidence="ECO:0000250|UniProtKB:Q3TFD2"
FT   MOTIF           220..223
FT                   /note="EGTC motif"
FT   COMPBIAS        518..529
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        530..544
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         404
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         406
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         408
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         410
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         415
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         441
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         443
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         445
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         447
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         452
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   VAR_SEQ         1..270
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:17974005"
FT                   /id="VSP_019912"
FT   VARIANT         163
FT                   /note="M -> I (in dbSNP:rs837550)"
FT                   /id="VAR_027058"
SQ   SEQUENCE   544 AA;  60208 MW;  B823D86272A739C0 CRC64;
     MSRCAQAAEV AATVPGAGVG NVGLRPPMVP RQASFFPPPV PNPFVQQTQI GSARRVQIVL
     LGIILLPIRV LLVALILLLA WPFAAISTVC CPEKLTHPIT GWRRKITQTA LKFLGRAMFF
     SMGFIVAVKG KIASPLEAPV FVAAPHSTFF DGIACVVAGL PSMVSRNENA QVPLIGRLLR
     AVQPVLVSRV DPDSRKNTIN EIIKRTTSGG EWPQILVFPE GTCTNRSCLI TFKPGAFIPG
     VPVQPVLLRY PNKLDTVTWT WQGYTFIQLC MLTFCQLFTK VEVEFMPVQV PNDEEKNDPV
     LFANKVRNLM AEALGIPVTD HTYEDCRLMI SAGQLTLPME AGLVEFTKIS RKLKLDWDGV
     RKHLDEYASI ASSSKGGRIG IEEFAKYLKL PVSDVLRQLF ALFDRNHDGS IDFREYVIGL
     AVLCNPSNTE EIIQVAFKLF DVDEDGYITE EEFSTILQAS LGVPDLDVSG LFKEIAQGDS
     ISYEEFKSFA LKHPEYAKIF TTYLDLQTCH VFSLPKEVQT TPSTASNKVS PEKHEESTSD
     KKDD
//
